| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 126 | 2023 | 1268 | 20.430 |
Why?
|
| Liver Cirrhosis | 57 | 2024 | 297 | 10.710 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 50 | 2024 | 212 | 10.700 |
Why?
|
| Hepatitis C | 49 | 2023 | 208 | 10.160 |
Why?
|
| Hepatitis C, Chronic | 38 | 2023 | 126 | 8.850 |
Why?
|
| Fatty Liver | 36 | 2023 | 125 | 7.850 |
Why?
|
| Antiviral Agents | 42 | 2023 | 510 | 7.580 |
Why?
|
| Liver | 47 | 2024 | 1230 | 5.530 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2023 | 384 | 5.140 |
Why?
|
| Liver Neoplasms | 21 | 2023 | 736 | 4.460 |
Why?
|
| Hepacivirus | 36 | 2023 | 159 | 4.100 |
Why?
|
| End Stage Liver Disease | 12 | 2023 | 61 | 3.570 |
Why?
|
| Graft Survival | 27 | 2022 | 884 | 3.250 |
Why?
|
| Ribavirin | 18 | 2023 | 57 | 2.910 |
Why?
|
| Metabolic Syndrome | 9 | 2019 | 142 | 2.800 |
Why?
|
| Immunosuppressive Agents | 19 | 2018 | 977 | 2.780 |
Why?
|
| Graft Rejection | 25 | 2019 | 1065 | 2.730 |
Why?
|
| Obesity | 20 | 2023 | 964 | 2.670 |
Why?
|
| Liver Diseases, Alcoholic | 6 | 2023 | 24 | 2.660 |
Why?
|
| Tissue Donors | 13 | 2022 | 463 | 2.630 |
Why?
|
| Insulin Resistance | 12 | 2023 | 377 | 2.580 |
Why?
|
| Interleukins | 7 | 2013 | 134 | 2.580 |
Why?
|
| Liver Failure | 14 | 2017 | 78 | 2.390 |
Why?
|
| Humans | 247 | 2024 | 86653 | 2.320 |
Why?
|
| Recurrence | 34 | 2019 | 1139 | 1.870 |
Why?
|
| Male | 136 | 2021 | 40973 | 1.770 |
Why?
|
| Cardiovascular Diseases | 9 | 2017 | 827 | 1.700 |
Why?
|
| Hepatitis E | 4 | 2015 | 9 | 1.700 |
Why?
|
| Viremia | 7 | 2022 | 54 | 1.660 |
Why?
|
| Female | 133 | 2021 | 44537 | 1.650 |
Why?
|
| Middle Aged | 106 | 2021 | 25028 | 1.630 |
Why?
|
| Postoperative Complications | 23 | 2018 | 2207 | 1.540 |
Why?
|
| Sofosbuvir | 10 | 2023 | 18 | 1.500 |
Why?
|
| Liver Diseases | 8 | 2021 | 238 | 1.490 |
Why?
|
| Risk Factors | 39 | 2022 | 5417 | 1.460 |
Why?
|
| Adult | 92 | 2024 | 25649 | 1.450 |
Why?
|
| Treatment Outcome | 47 | 2024 | 7993 | 1.450 |
Why?
|
| RNA, Viral | 20 | 2021 | 327 | 1.340 |
Why?
|
| Uridine Monophosphate | 5 | 2016 | 9 | 1.330 |
Why?
|
| Interferon-alpha | 10 | 2015 | 233 | 1.300 |
Why?
|
| Sirolimus | 3 | 2013 | 169 | 1.230 |
Why?
|
| Tacrolimus | 5 | 2017 | 373 | 1.190 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2016 | 351 | 1.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 3 | 2020 | 69 | 1.160 |
Why?
|
| Genotype | 22 | 2023 | 1851 | 1.160 |
Why?
|
| Waiting Lists | 6 | 2017 | 175 | 1.160 |
Why?
|
| Donor Selection | 2 | 2021 | 67 | 1.100 |
Why?
|
| United States | 29 | 2022 | 6674 | 1.090 |
Why?
|
| Drug Therapy, Combination | 20 | 2023 | 894 | 1.080 |
Why?
|
| Patient Selection | 7 | 2020 | 686 | 1.060 |
Why?
|
| Amino Acids, Branched-Chain | 5 | 2011 | 7 | 1.040 |
Why?
|
| Risk Assessment | 14 | 2021 | 2262 | 1.020 |
Why?
|
| Lipase | 3 | 2013 | 22 | 1.020 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 4 | 2016 | 16 | 0.990 |
Why?
|
| Carbamates | 4 | 2016 | 19 | 0.990 |
Why?
|
| Tissue and Organ Procurement | 4 | 2019 | 311 | 0.950 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2021 | 122 | 0.940 |
Why?
|
| Prevalence | 17 | 2017 | 1239 | 0.930 |
Why?
|
| Nutritional Status | 4 | 2013 | 83 | 0.910 |
Why?
|
| Glomerular Filtration Rate | 4 | 2014 | 385 | 0.910 |
Why?
|
| Viral Load | 12 | 2021 | 148 | 0.910 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 48 | 0.900 |
Why?
|
| Proportional Hazards Models | 13 | 2021 | 859 | 0.890 |
Why?
|
| Mycophenolic Acid | 4 | 2013 | 87 | 0.870 |
Why?
|
| Hepatocytes | 9 | 2022 | 127 | 0.870 |
Why?
|
| Hepatitis B, Chronic | 2 | 2020 | 32 | 0.850 |
Why?
|
| Diabetes Mellitus | 7 | 2022 | 806 | 0.850 |
Why?
|
| Fatty Liver, Alcoholic | 3 | 2016 | 7 | 0.850 |
Why?
|
| Adipokines | 2 | 2014 | 19 | 0.840 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2015 | 17 | 0.840 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2015 | 2357 | 0.830 |
Why?
|
| Metformin | 2 | 2023 | 128 | 0.830 |
Why?
|
| Time Factors | 19 | 2021 | 5210 | 0.820 |
Why?
|
| Food-Drug Interactions | 1 | 2021 | 18 | 0.800 |
Why?
|
| Living Donors | 6 | 2021 | 339 | 0.800 |
Why?
|
| Prospective Studies | 24 | 2021 | 4213 | 0.790 |
Why?
|
| Keratan Sulfate | 2 | 2012 | 6 | 0.790 |
Why?
|
| Biopsy | 20 | 2024 | 1163 | 0.780 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 2 | 2012 | 38 | 0.780 |
Why?
|
| Weight Gain | 3 | 2020 | 123 | 0.770 |
Why?
|
| Interferons | 10 | 2014 | 133 | 0.760 |
Why?
|
| Tenofovir | 1 | 2020 | 7 | 0.760 |
Why?
|
| Drug Compounding | 1 | 2021 | 78 | 0.750 |
Why?
|
| Disease Progression | 13 | 2018 | 1531 | 0.740 |
Why?
|
| Everolimus | 2 | 2017 | 40 | 0.740 |
Why?
|
| Alanine | 1 | 2020 | 85 | 0.740 |
Why?
|
| Polyethylene Glycols | 7 | 2015 | 363 | 0.740 |
Why?
|
| Aged | 47 | 2019 | 18415 | 0.740 |
Why?
|
| Dehydroepiandrosterone | 2 | 2011 | 51 | 0.720 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 378 | 0.720 |
Why?
|
| Multivariate Analysis | 10 | 2015 | 999 | 0.710 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 57 | 0.700 |
Why?
|
| Bariatric Surgery | 3 | 2019 | 194 | 0.700 |
Why?
|
| Transplant Recipients | 3 | 2021 | 122 | 0.700 |
Why?
|
| Dietary Supplements | 5 | 2012 | 128 | 0.700 |
Why?
|
| Membrane Proteins | 4 | 2013 | 1196 | 0.680 |
Why?
|
| Obesity, Morbid | 4 | 2018 | 225 | 0.660 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2021 | 568 | 0.660 |
Why?
|
| Follow-Up Studies | 20 | 2021 | 3640 | 0.660 |
Why?
|
| Elasticity Imaging Techniques | 4 | 2018 | 59 | 0.640 |
Why?
|
| Health Care Costs | 1 | 2020 | 238 | 0.630 |
Why?
|
| Global Health | 2 | 2017 | 193 | 0.630 |
Why?
|
| Fibroblast Growth Factors | 2 | 2018 | 80 | 0.630 |
Why?
|
| Adiponectin | 3 | 2014 | 24 | 0.610 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2015 | 36 | 0.600 |
Why?
|
| Hepatitis | 3 | 2024 | 35 | 0.590 |
Why?
|
| Oligopeptides | 3 | 2014 | 179 | 0.590 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 371 | 0.580 |
Why?
|
| Population Surveillance | 1 | 2018 | 219 | 0.570 |
Why?
|
| Fluorenes | 2 | 2016 | 8 | 0.570 |
Why?
|
| Recombinant Proteins | 10 | 2015 | 1014 | 0.550 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2013 | 14 | 0.550 |
Why?
|
| Insulin | 10 | 2022 | 1160 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 582 | 0.540 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 376 | 0.520 |
Why?
|
| Diet, High-Fat | 2 | 2017 | 114 | 0.520 |
Why?
|
| Benzimidazoles | 2 | 2016 | 140 | 0.510 |
Why?
|
| Proline | 2 | 2013 | 57 | 0.510 |
Why?
|
| Biomarkers | 10 | 2018 | 1718 | 0.510 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 129 | 0.510 |
Why?
|
| Medically Uninsured | 1 | 2015 | 58 | 0.510 |
Why?
|
| Cholestasis | 2 | 2017 | 47 | 0.500 |
Why?
|
| Hepatic Encephalopathy | 4 | 2023 | 40 | 0.500 |
Why?
|
| Body Mass Index | 9 | 2018 | 770 | 0.490 |
Why?
|
| Survival Rate | 12 | 2021 | 1863 | 0.490 |
Why?
|
| Transplantation, Homologous | 9 | 2021 | 996 | 0.490 |
Why?
|
| Sarcopenia | 1 | 2014 | 13 | 0.480 |
Why?
|
| Liver Cirrhosis, Experimental | 2 | 2016 | 7 | 0.480 |
Why?
|
| Insurance Coverage | 1 | 2015 | 117 | 0.480 |
Why?
|
| Gastroenterology | 2 | 2021 | 134 | 0.480 |
Why?
|
| Insurance, Health | 1 | 2015 | 160 | 0.480 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 160 | 0.470 |
Why?
|
| Nephrons | 1 | 2013 | 18 | 0.470 |
Why?
|
| Imidazoles | 3 | 2019 | 162 | 0.470 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 72 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1375 | 0.460 |
Why?
|
| Prognosis | 15 | 2021 | 3680 | 0.460 |
Why?
|
| Lipogenesis | 1 | 2013 | 22 | 0.460 |
Why?
|
| Gastric Bypass | 2 | 2012 | 110 | 0.460 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2019 | 860 | 0.450 |
Why?
|
| Severity of Illness Index | 14 | 2019 | 1801 | 0.450 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 54 | 0.450 |
Why?
|
| Registries | 6 | 2019 | 703 | 0.440 |
Why?
|
| Steroids | 1 | 2013 | 177 | 0.430 |
Why?
|
| Proteomics | 2 | 2011 | 212 | 0.430 |
Why?
|
| Proteins | 5 | 2001 | 777 | 0.420 |
Why?
|
| Renal Insufficiency | 4 | 2018 | 114 | 0.410 |
Why?
|
| Drug Interactions | 4 | 2019 | 248 | 0.410 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2018 | 166 | 0.410 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2011 | 10 | 0.410 |
Why?
|
| Cohort Studies | 10 | 2020 | 2767 | 0.410 |
Why?
|
| Transplantation | 2 | 2011 | 39 | 0.400 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2020 | 19 | 0.400 |
Why?
|
| Asia | 3 | 2020 | 95 | 0.400 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 394 | 0.400 |
Why?
|
| Growth Hormone | 1 | 2011 | 97 | 0.400 |
Why?
|
| Biliopancreatic Diversion | 1 | 2011 | 4 | 0.400 |
Why?
|
| Retrospective Studies | 21 | 2022 | 8491 | 0.400 |
Why?
|
| Neutrons | 1 | 2011 | 58 | 0.390 |
Why?
|
| Radiation Protection | 1 | 2011 | 25 | 0.390 |
Why?
|
| Aging | 1 | 2015 | 691 | 0.390 |
Why?
|
| Gastroplasty | 1 | 2011 | 21 | 0.390 |
Why?
|
| Troponin I | 1 | 2011 | 27 | 0.390 |
Why?
|
| C-Reactive Protein | 4 | 2014 | 190 | 0.390 |
Why?
|
| Troponin | 1 | 2010 | 24 | 0.370 |
Why?
|
| Drug Resistance, Viral | 4 | 2020 | 51 | 0.370 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1806 | 0.370 |
Why?
|
| Alleles | 2 | 2013 | 1128 | 0.370 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 3 | 0.370 |
Why?
|
| Radiation Dosage | 1 | 2011 | 227 | 0.360 |
Why?
|
| Drug Administration Schedule | 8 | 2017 | 916 | 0.360 |
Why?
|
| Amino Acids | 7 | 2023 | 252 | 0.360 |
Why?
|
| Kidney | 2 | 2013 | 1242 | 0.360 |
Why?
|
| Primary Graft Dysfunction | 1 | 2009 | 27 | 0.360 |
Why?
|
| Nutrition Surveys | 3 | 2015 | 114 | 0.350 |
Why?
|
| Kidney Diseases | 1 | 2013 | 418 | 0.350 |
Why?
|
| Leucine | 7 | 2001 | 67 | 0.350 |
Why?
|
| Kidney Transplantation | 5 | 2019 | 849 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2024 | 1961 | 0.350 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 26 | 0.350 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 95 | 0.340 |
Why?
|
| Blood Glucose | 7 | 2017 | 873 | 0.340 |
Why?
|
| Reoperation | 6 | 2012 | 597 | 0.340 |
Why?
|
| Long-Term Care | 1 | 2009 | 61 | 0.340 |
Why?
|
| Dietary Fats | 1 | 2009 | 135 | 0.340 |
Why?
|
| Apolipoproteins | 2 | 2014 | 38 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1036 | 0.330 |
Why?
|
| Consensus | 3 | 2019 | 335 | 0.330 |
Why?
|
| Double-Blind Method | 7 | 2024 | 1823 | 0.330 |
Why?
|
| Health Care Reform | 1 | 2009 | 90 | 0.330 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 696 | 0.320 |
Why?
|
| Liver Cirrhosis, Alcoholic | 3 | 2013 | 23 | 0.320 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 819 | 0.310 |
Why?
|
| Antibodies | 1 | 2010 | 350 | 0.310 |
Why?
|
| Virus Replication | 3 | 2006 | 319 | 0.310 |
Why?
|
| Genetic Variation | 3 | 2013 | 1351 | 0.310 |
Why?
|
| Glucagon | 2 | 1998 | 111 | 0.300 |
Why?
|
| Immunoglobulins | 4 | 2013 | 148 | 0.300 |
Why?
|
| Animals | 23 | 2024 | 26589 | 0.300 |
Why?
|
| Survival Analysis | 8 | 2014 | 1538 | 0.300 |
Why?
|
| Secondary Prevention | 5 | 2007 | 162 | 0.300 |
Why?
|
| Benzamides | 2 | 2018 | 229 | 0.300 |
Why?
|
| Age Factors | 7 | 2011 | 1851 | 0.290 |
Why?
|
| Fibrosis | 6 | 2023 | 203 | 0.290 |
Why?
|
| Hypoglycemic Agents | 4 | 2016 | 378 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 865 | 0.290 |
Why?
|
| Diabetes Complications | 4 | 2021 | 207 | 0.290 |
Why?
|
| Protein Biosynthesis | 4 | 2002 | 378 | 0.290 |
Why?
|
| Adolescent | 11 | 2018 | 8982 | 0.280 |
Why?
|
| Incidence | 9 | 2019 | 1577 | 0.280 |
Why?
|
| Leptin | 3 | 2014 | 105 | 0.280 |
Why?
|
| Alkaline Phosphatase | 1 | 2006 | 132 | 0.280 |
Why?
|
| Pyridines | 2 | 2018 | 310 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2021 | 814 | 0.270 |
Why?
|
| Calcineurin Inhibitors | 3 | 2015 | 54 | 0.270 |
Why?
|
| Cause of Death | 4 | 2016 | 277 | 0.270 |
Why?
|
| Transcription Factors | 2 | 2013 | 1565 | 0.270 |
Why?
|
| Logistic Models | 2 | 2012 | 1187 | 0.270 |
Why?
|
| Young Adult | 9 | 2021 | 5977 | 0.270 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 155 | 0.270 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 295 | 0.270 |
Why?
|
| Heart Transplantation | 3 | 2021 | 705 | 0.260 |
Why?
|
| Regression Analysis | 5 | 2021 | 596 | 0.260 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2011 | 199 | 0.260 |
Why?
|
| Hypertension, Portal | 2 | 2017 | 47 | 0.260 |
Why?
|
| Preoperative Care | 3 | 2017 | 397 | 0.260 |
Why?
|
| Alanine Transaminase | 3 | 2012 | 73 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2018 | 930 | 0.250 |
Why?
|
| Postoperative Period | 4 | 2016 | 303 | 0.250 |
Why?
|
| Body Weight | 3 | 2023 | 459 | 0.250 |
Why?
|
| Hepatitis, Viral, Human | 3 | 2000 | 25 | 0.250 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 1673 | 0.250 |
Why?
|
| Pyridazines | 1 | 2024 | 22 | 0.240 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 689 | 0.240 |
Why?
|
| Uracil | 1 | 2024 | 72 | 0.240 |
Why?
|
| Mice | 12 | 2024 | 11356 | 0.230 |
Why?
|
| Lactulose | 1 | 2023 | 19 | 0.230 |
Why?
|
| Biliary Tract | 1 | 2003 | 13 | 0.230 |
Why?
|
| Biliary Atresia | 1 | 2003 | 22 | 0.230 |
Why?
|
| Nutritional Support | 1 | 2003 | 17 | 0.230 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 1991 | 0.230 |
Why?
|
| Hormones | 2 | 2002 | 141 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1686 | 0.220 |
Why?
|
| Malnutrition | 2 | 2013 | 34 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2022 | 534 | 0.220 |
Why?
|
| Minnesota | 2 | 2013 | 46 | 0.220 |
Why?
|
| Palmitates | 3 | 2011 | 18 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2011 | 645 | 0.210 |
Why?
|
| Immunoglobulin G | 3 | 2011 | 456 | 0.210 |
Why?
|
| Organ Preservation Solutions | 1 | 2022 | 28 | 0.210 |
Why?
|
| Adipocytes | 1 | 2023 | 155 | 0.210 |
Why?
|
| DNA Virus Infections | 2 | 1999 | 6 | 0.210 |
Why?
|
| Blood Donors | 2 | 2000 | 26 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 5 | 2017 | 3095 | 0.210 |
Why?
|
| Hepatitis B | 2 | 2019 | 74 | 0.210 |
Why?
|
| Child | 7 | 2017 | 6928 | 0.210 |
Why?
|
| Pregnancy | 3 | 2015 | 2894 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2016 | 684 | 0.210 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 2232 | 0.210 |
Why?
|
| Flaviviridae | 2 | 1999 | 3 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 1313 | 0.200 |
Why?
|
| Resistin | 2 | 2014 | 14 | 0.200 |
Why?
|
| Capsules | 1 | 2021 | 38 | 0.200 |
Why?
|
| Diet, Mediterranean | 1 | 2021 | 6 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2018 | 5 | 0.200 |
Why?
|
| Lumican | 2 | 2012 | 2 | 0.200 |
Why?
|
| Brain Death | 1 | 2022 | 69 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 144 | 0.200 |
Why?
|
| Diet | 2 | 2016 | 443 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 6 | 2009 | 927 | 0.200 |
Why?
|
| Cholesterol | 1 | 2023 | 356 | 0.200 |
Why?
|
| Risk | 3 | 2009 | 674 | 0.200 |
Why?
|
| Vitamin E | 3 | 2016 | 35 | 0.190 |
Why?
|
| Gene Expression | 3 | 2011 | 1284 | 0.190 |
Why?
|
| Apolipoprotein B-100 | 3 | 2014 | 12 | 0.190 |
Why?
|
| Sulfatases | 1 | 2020 | 4 | 0.190 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 143 | 0.190 |
Why?
|
| ROC Curve | 4 | 2018 | 752 | 0.190 |
Why?
|
| Collagen | 4 | 2018 | 269 | 0.190 |
Why?
|
| Nasturtium | 1 | 2020 | 4 | 0.190 |
Why?
|
| Fasciola hepatica | 1 | 2020 | 5 | 0.190 |
Why?
|
| Antibodies, Helminth | 1 | 2020 | 11 | 0.190 |
Why?
|
| Fascioliasis | 1 | 2020 | 6 | 0.190 |
Why?
|
| Dyspepsia | 1 | 2020 | 10 | 0.190 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 399 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1621 | 0.180 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2019 | 2 | 0.180 |
Why?
|
| Sulfoxides | 1 | 2019 | 6 | 0.180 |
Why?
|
| Benzothiazoles | 1 | 2019 | 17 | 0.180 |
Why?
|
| Fibrinogen | 3 | 2013 | 56 | 0.180 |
Why?
|
| Tablets | 1 | 2021 | 118 | 0.180 |
Why?
|
| Comorbidity | 3 | 2016 | 943 | 0.180 |
Why?
|
| Eosinophilia | 1 | 2020 | 84 | 0.180 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2010 | 5 | 0.180 |
Why?
|
| Isoxazoles | 1 | 2019 | 77 | 0.180 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 6509 | 0.180 |
Why?
|
| Cohort Effect | 1 | 2019 | 6 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 53 | 0.170 |
Why?
|
| Basal Metabolism | 1 | 1998 | 20 | 0.170 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2021 | 225 | 0.170 |
Why?
|
| Isobutyrates | 1 | 2018 | 1 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 143 | 0.170 |
Why?
|
| Oxazoles | 1 | 2018 | 19 | 0.170 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2018 | 24 | 0.170 |
Why?
|
| Signal Transduction | 4 | 2017 | 3243 | 0.160 |
Why?
|
| Obesity Management | 1 | 2018 | 1 | 0.160 |
Why?
|
| Energy Metabolism | 2 | 2017 | 271 | 0.160 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 5 | 0.160 |
Why?
|
| Aging, Premature | 1 | 2018 | 7 | 0.160 |
Why?
|
| Reference Values | 3 | 2008 | 674 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2018 | 31 | 0.160 |
Why?
|
| Drug Combinations | 2 | 2015 | 224 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 3362 | 0.160 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 351 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 2 | 2015 | 55 | 0.160 |
Why?
|
| Publishing | 2 | 2009 | 90 | 0.160 |
Why?
|
| Nutrition Assessment | 2 | 2012 | 21 | 0.160 |
Why?
|
| Intestine, Small | 1 | 2000 | 303 | 0.160 |
Why?
|
| Internal Medicine | 1 | 2021 | 347 | 0.150 |
Why?
|
| Portal Pressure | 1 | 2017 | 3 | 0.150 |
Why?
|
| Glycosylation | 1 | 2017 | 129 | 0.150 |
Why?
|
| Sustained Virologic Response | 4 | 2018 | 8 | 0.150 |
Why?
|
| Hepatic Veins | 1 | 2017 | 27 | 0.150 |
Why?
|
| Myosin Heavy Chains | 1 | 1997 | 88 | 0.150 |
Why?
|
| Mitochondria, Liver | 1 | 2017 | 27 | 0.150 |
Why?
|
| Hemoglobins | 1 | 2017 | 179 | 0.150 |
Why?
|
| Cyclosporine | 2 | 2011 | 234 | 0.150 |
Why?
|
| Cholangitis, Sclerosing | 3 | 2005 | 52 | 0.150 |
Why?
|
| Apoptosis | 4 | 2011 | 1683 | 0.150 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1996 | 5 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2014 | 839 | 0.150 |
Why?
|
| Curriculum | 1 | 2021 | 539 | 0.150 |
Why?
|
| Adiposity | 1 | 2017 | 70 | 0.150 |
Why?
|
| Gallbladder Neoplasms | 1 | 2016 | 22 | 0.150 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1996 | 36 | 0.140 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 468 | 0.140 |
Why?
|
| Immunocompromised Host | 2 | 2015 | 140 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 176 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 384 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 589 | 0.140 |
Why?
|
| Mass Screening | 3 | 2017 | 618 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 173 | 0.140 |
Why?
|
| Lysophosphatidylcholines | 1 | 2016 | 18 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 1376 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 509 | 0.140 |
Why?
|
| Organ Size | 1 | 2017 | 364 | 0.140 |
Why?
|
| Transplants | 1 | 2016 | 40 | 0.140 |
Why?
|
| Internationality | 1 | 2016 | 69 | 0.140 |
Why?
|
| Kinetics | 5 | 2014 | 1513 | 0.140 |
Why?
|
| Palmitic Acid | 1 | 2016 | 27 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2017 | 221 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2015 | 37 | 0.140 |
Why?
|
| Hepatitis E virus | 1 | 2015 | 6 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 66 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2014 | 754 | 0.140 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 79 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2018 | 370 | 0.130 |
Why?
|
| Lipids | 1 | 2017 | 269 | 0.130 |
Why?
|
| Compassionate Use Trials | 1 | 2015 | 8 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1464 | 0.130 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 449 | 0.130 |
Why?
|
| Organ Transplantation | 2 | 2017 | 265 | 0.130 |
Why?
|
| Species Specificity | 1 | 2017 | 678 | 0.130 |
Why?
|
| Extracellular Vesicles | 1 | 2016 | 42 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 1753 | 0.130 |
Why?
|
| New Zealand | 1 | 2014 | 22 | 0.130 |
Why?
|
| Spain | 1 | 2014 | 33 | 0.130 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 275 | 0.130 |
Why?
|
| Antioxidants | 1 | 2016 | 223 | 0.130 |
Why?
|
| Monocytes | 1 | 2016 | 216 | 0.130 |
Why?
|
| Alcoholism | 1 | 2016 | 172 | 0.130 |
Why?
|
| Family | 1 | 2016 | 311 | 0.130 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 797 | 0.130 |
Why?
|
| Dyslipidemias | 2 | 2020 | 109 | 0.130 |
Why?
|
| Metalloendopeptidases | 1 | 2014 | 45 | 0.130 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 68 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 267 | 0.120 |
Why?
|
| Pedigree | 1 | 2016 | 966 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2017 | 272 | 0.120 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 1169 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 394 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 112 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2015 | 182 | 0.120 |
Why?
|
| Arteries | 1 | 2015 | 177 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 319 | 0.120 |
Why?
|
| Endoscopy | 2 | 2014 | 332 | 0.120 |
Why?
|
| Hepatectomy | 3 | 2019 | 166 | 0.120 |
Why?
|
| Ascites | 2 | 2018 | 55 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 481 | 0.120 |
Why?
|
| Glucose | 3 | 2022 | 638 | 0.120 |
Why?
|
| DNA, Viral | 4 | 2019 | 265 | 0.120 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 78 | 0.120 |
Why?
|
| Probability | 3 | 2007 | 355 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2013 | 54 | 0.110 |
Why?
|
| Mesocricetus | 2 | 2023 | 107 | 0.110 |
Why?
|
| Social Class | 1 | 2013 | 128 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2018 | 628 | 0.110 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2013 | 52 | 0.110 |
Why?
|
| Hypertension | 3 | 2010 | 1142 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 44 | 0.110 |
Why?
|
| Educational Status | 1 | 2013 | 188 | 0.110 |
Why?
|
| Nutrition Disorders | 1 | 2012 | 16 | 0.110 |
Why?
|
| Carbon Tetrachloride | 1 | 2012 | 7 | 0.110 |
Why?
|
| Sound | 1 | 2013 | 26 | 0.110 |
Why?
|
| Aneurysm, False | 1 | 2013 | 54 | 0.110 |
Why?
|
| Noise | 1 | 2013 | 27 | 0.110 |
Why?
|
| Algorithms | 2 | 2020 | 1830 | 0.110 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2012 | 4 | 0.110 |
Why?
|
| Intestines | 1 | 2016 | 411 | 0.110 |
Why?
|
| Hepatic Artery | 1 | 2013 | 83 | 0.110 |
Why?
|
| Nutrition Therapy | 1 | 2012 | 11 | 0.110 |
Why?
|
| Lipid Metabolism | 2 | 2004 | 197 | 0.110 |
Why?
|
| Animal Husbandry | 1 | 2013 | 25 | 0.110 |
Why?
|
| Carbon Isotopes | 4 | 2001 | 76 | 0.110 |
Why?
|
| Liver Circulation | 1 | 2012 | 30 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2012 | 130 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 736 | 0.110 |
Why?
|
| Plant Lectins | 2 | 2015 | 11 | 0.110 |
Why?
|
| Guanine | 1 | 2013 | 208 | 0.110 |
Why?
|
| Pulmonary Circulation | 1 | 2012 | 86 | 0.110 |
Why?
|
| Methylprednisolone | 2 | 2003 | 66 | 0.110 |
Why?
|
| Phenotype | 3 | 2016 | 2380 | 0.110 |
Why?
|
| Cytomegalovirus | 2 | 2002 | 76 | 0.110 |
Why?
|
| Pressure | 1 | 2013 | 165 | 0.110 |
Why?
|
| Cricetinae | 2 | 2023 | 560 | 0.110 |
Why?
|
| alpha-Fetoproteins | 2 | 2015 | 45 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 87 | 0.110 |
Why?
|
| Propensity Score | 1 | 2012 | 136 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 307 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2013 | 80 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 176 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1004 | 0.100 |
Why?
|
| Nephrectomy | 1 | 2014 | 294 | 0.100 |
Why?
|
| Isoquinolines | 1 | 2012 | 72 | 0.100 |
Why?
|
| Sex Factors | 2 | 2013 | 1054 | 0.100 |
Why?
|
| Complement C4 | 1 | 2011 | 10 | 0.100 |
Why?
|
| PPAR gamma | 1 | 2011 | 66 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 639 | 0.100 |
Why?
|
| Boron | 1 | 2011 | 3 | 0.100 |
Why?
|
| Polyethylene | 1 | 2011 | 8 | 0.100 |
Why?
|
| Unfolded Protein Response | 1 | 2011 | 39 | 0.100 |
Why?
|
| Particle Accelerators | 1 | 2011 | 16 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2006 | 1204 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2011 | 715 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2015 | 285 | 0.100 |
Why?
|
| Photons | 1 | 2011 | 46 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2013 | 233 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 2271 | 0.100 |
Why?
|
| Aquaporin 1 | 1 | 2010 | 5 | 0.100 |
Why?
|
| Alcoholics | 1 | 2010 | 1 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 67 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 508 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2012 | 3613 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 263 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 106 | 0.090 |
Why?
|
| Interferon-gamma | 1 | 2012 | 444 | 0.090 |
Why?
|
| Cell Movement | 2 | 2010 | 758 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1169 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2003 | 352 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2012 | 300 | 0.090 |
Why?
|
| Blood Group Incompatibility | 1 | 2009 | 18 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2009 | 24 | 0.090 |
Why?
|
| Heart Failure | 1 | 2019 | 1204 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2013 | 24 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2010 | 218 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 62 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2009 | 39 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 235 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2012 | 711 | 0.080 |
Why?
|
| Mitochondria | 2 | 2003 | 535 | 0.080 |
Why?
|
| Weight Loss | 3 | 2018 | 229 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 103 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 924 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 346 | 0.080 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2008 | 16 | 0.080 |
Why?
|
| Exercise | 2 | 2018 | 315 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 301 | 0.080 |
Why?
|
| Contraindications | 1 | 2008 | 72 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 429 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 296 | 0.080 |
Why?
|
| Protein Precursors | 2 | 2015 | 143 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 353 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 435 | 0.080 |
Why?
|
| Somatostatin | 2 | 1998 | 55 | 0.080 |
Why?
|
| Cell Line | 1 | 2012 | 2469 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 168 | 0.080 |
Why?
|
| Macrophages | 2 | 2024 | 557 | 0.070 |
Why?
|
| Hepatitis B virus | 2 | 2019 | 43 | 0.070 |
Why?
|
| Coinfection | 2 | 2017 | 58 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1019 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1579 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1981 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2006 | 93 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2022 | 294 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2426 | 0.070 |
Why?
|
| Safety | 2 | 2007 | 152 | 0.070 |
Why?
|
| Length of Stay | 3 | 2014 | 703 | 0.070 |
Why?
|
| Japan | 1 | 2006 | 307 | 0.070 |
Why?
|
| Apolipoproteins B | 2 | 2002 | 38 | 0.070 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2005 | 19 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 552 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 2 | 2002 | 8 | 0.060 |
Why?
|
| Hypophosphatemia | 1 | 2004 | 8 | 0.060 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 57 | 0.060 |
Why?
|
| Temperance | 1 | 2004 | 7 | 0.060 |
Why?
|
| Diet, Reducing | 1 | 2004 | 31 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 547 | 0.060 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2024 | 17 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2005 | 112 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 161 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2004 | 251 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2003 | 71 | 0.060 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2024 | 81 | 0.060 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2003 | 25 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 1195 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 526 | 0.060 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 40 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 33 | 0.060 |
Why?
|
| Viral Interference | 1 | 2002 | 4 | 0.060 |
Why?
|
| Immunocompetence | 1 | 2002 | 27 | 0.060 |
Why?
|
| Age Distribution | 1 | 2003 | 204 | 0.060 |
Why?
|
| Disease Management | 2 | 2017 | 327 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 546 | 0.050 |
Why?
|
| Raffinose | 1 | 2022 | 24 | 0.050 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2022 | 4 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2014 | 2819 | 0.050 |
Why?
|
| Potassium Chloride | 1 | 2022 | 87 | 0.050 |
Why?
|
| Physician Assistants | 1 | 2002 | 19 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2002 | 31 | 0.050 |
Why?
|
| Neoplasms | 2 | 2014 | 2898 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2002 | 91 | 0.050 |
Why?
|
| Glutathione | 1 | 2022 | 104 | 0.050 |
Why?
|
| Allopurinol | 1 | 2022 | 80 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2002 | 53 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1384 | 0.050 |
Why?
|
| Caproates | 2 | 2001 | 7 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2002 | 156 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 145 | 0.050 |
Why?
|
| Organ Preservation | 1 | 2022 | 83 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2002 | 60 | 0.050 |
Why?
|
| RNA Interference | 2 | 2016 | 369 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2004 | 448 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2002 | 130 | 0.050 |
Why?
|
| Anemia | 1 | 2002 | 128 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 167 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 1924 | 0.050 |
Why?
|
| Bilirubin | 1 | 2021 | 125 | 0.050 |
Why?
|
| Quality of Life | 3 | 2018 | 1585 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2001 | 281 | 0.050 |
Why?
|
| Muscle Proteins | 2 | 2001 | 132 | 0.050 |
Why?
|
| Phenylalanine | 2 | 2001 | 37 | 0.050 |
Why?
|
| Fast Foods | 1 | 2020 | 2 | 0.050 |
Why?
|
| Cell Size | 1 | 2000 | 65 | 0.050 |
Why?
|
| Antiplatyhelmintic Agents | 1 | 2020 | 6 | 0.050 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 55 | 0.050 |
Why?
|
| Life Cycle Stages | 1 | 2020 | 16 | 0.050 |
Why?
|
| Anthropometry | 1 | 2000 | 74 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 153 | 0.050 |
Why?
|
| Circoviridae Infections | 1 | 2000 | 3 | 0.050 |
Why?
|
| Creatinine | 2 | 2013 | 339 | 0.050 |
Why?
|
| Hand Strength | 1 | 2000 | 51 | 0.050 |
Why?
|
| Diet, Western | 1 | 2020 | 37 | 0.050 |
Why?
|
| Binding Sites | 2 | 2014 | 1098 | 0.050 |
Why?
|
| Sodium Bicarbonate | 1 | 2000 | 10 | 0.050 |
Why?
|
| Hepatitis B e Antigens | 1 | 2019 | 8 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2000 | 99 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2010 | 47 | 0.050 |
Why?
|
| Receptors, CCR2 | 1 | 2019 | 35 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 139 | 0.040 |
Why?
|
| Travel | 1 | 2020 | 68 | 0.040 |
Why?
|
| Hematuria | 1 | 2000 | 49 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 363 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2002 | 695 | 0.040 |
Why?
|
| Urologic Diseases | 1 | 2000 | 45 | 0.040 |
Why?
|
| Adenosine | 1 | 2022 | 225 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 225 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 159 | 0.040 |
Why?
|
| Urologic Neoplasms | 1 | 2000 | 77 | 0.040 |
Why?
|
| Calorimetry, Indirect | 1 | 1998 | 15 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2020 | 137 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 298 | 0.040 |
Why?
|
| Carnitine | 1 | 2018 | 14 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 506 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 826 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 117 | 0.040 |
Why?
|
| HIV Infections | 2 | 2017 | 772 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2003 | 971 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 746 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 172 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2002 | 383 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2018 | 39 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2017 | 41 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 71 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2000 | 337 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 1998 | 373 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2010 | 279 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 1998 | 157 | 0.040 |
Why?
|
| CpG Islands | 1 | 2018 | 151 | 0.040 |
Why?
|
| Utah | 1 | 2016 | 10 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2010 | 1106 | 0.040 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2016 | 12 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 677 | 0.040 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 1996 | 7 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 1170 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 421 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 429 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2016 | 33 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 72 | 0.040 |
Why?
|
| Models, Biological | 2 | 2018 | 1749 | 0.040 |
Why?
|
| Hydroxybutyrates | 1 | 1996 | 27 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2016 | 70 | 0.040 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1996 | 70 | 0.040 |
Why?
|
| Glycerol | 1 | 1996 | 32 | 0.040 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 4 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 1996 | 60 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 172 | 0.030 |
Why?
|
| Catecholamines | 1 | 1996 | 88 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 44 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1565 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 751 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 252 | 0.030 |
Why?
|
| Caspases | 1 | 2016 | 155 | 0.030 |
Why?
|
| Prothrombin | 1 | 2015 | 18 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2705 | 0.030 |
Why?
|
| Isoflurane | 1 | 1995 | 64 | 0.030 |
Why?
|
| Fluorescence Polarization | 1 | 2014 | 9 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 1995 | 95 | 0.030 |
Why?
|
| Allosteric Site | 1 | 2014 | 23 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 33 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2014 | 51 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1996 | 298 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 204 | 0.030 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 159 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 156 | 0.030 |
Why?
|
| Iothalamic Acid | 1 | 2013 | 11 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 124 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 287 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 896 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 778 | 0.030 |
Why?
|
| Pneumonia | 1 | 2015 | 179 | 0.030 |
Why?
|
| Lactates | 1 | 2013 | 37 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2014 | 347 | 0.030 |
Why?
|
| Models, Chemical | 1 | 2014 | 178 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2013 | 64 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 615 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 572 | 0.030 |
Why?
|
| Clostridium Infections | 1 | 2015 | 125 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 879 | 0.030 |
Why?
|
| Decontamination | 1 | 2013 | 9 | 0.030 |
Why?
|
| Infant | 2 | 1997 | 3047 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 485 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2014 | 276 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1221 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 2013 | 30 | 0.030 |
Why?
|
| Texas | 1 | 2013 | 101 | 0.030 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1992 | 9 | 0.030 |
Why?
|
| Gallstones | 1 | 1992 | 14 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 71 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2012 | 102 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 318 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2012 | 68 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 297 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2012 | 38 | 0.030 |
Why?
|
| Vasodilation | 1 | 2012 | 96 | 0.030 |
Why?
|
| Replicon | 1 | 2012 | 8 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 602 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.030 |
Why?
|
| Keto Acids | 2 | 2001 | 6 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 82 | 0.030 |
Why?
|
| Swine, Miniature | 2 | 2001 | 51 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 678 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 98 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 130 | 0.030 |
Why?
|
| Life Style | 1 | 2012 | 189 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 92 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 118 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 813 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 364 | 0.020 |
Why?
|
| Albumins | 1 | 2011 | 133 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2013 | 2379 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1457 | 0.020 |
Why?
|
| Osmosis | 1 | 2010 | 6 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2010 | 14 | 0.020 |
Why?
|
| Hepatic Stellate Cells | 1 | 2010 | 10 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 268 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 28 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2601 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2010 | 11 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 15 | 0.020 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Rodentia | 1 | 2010 | 42 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 134 | 0.020 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1286 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2010 | 119 | 0.020 |
Why?
|
| Swine | 2 | 2001 | 555 | 0.020 |
Why?
|
| Anthracenes | 1 | 2009 | 16 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 113 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 478 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 642 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 179 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 267 | 0.020 |
Why?
|
| Altruism | 1 | 2009 | 35 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 266 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 268 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 129 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2010 | 232 | 0.020 |
Why?
|
| Water | 1 | 2010 | 277 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2501 | 0.020 |
Why?
|
| Esophagus | 1 | 1989 | 102 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 250 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3992 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2010 | 227 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 425 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 116 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2010 | 666 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2007 | 130 | 0.020 |
Why?
|
| Base Sequence | 2 | 2000 | 2330 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 3030 | 0.020 |
Why?
|
| Liver Regeneration | 1 | 2004 | 32 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2007 | 328 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 238 | 0.020 |
Why?
|
| Phosphates | 1 | 2004 | 160 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1208 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 2002 | 33 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 451 | 0.010 |
Why?
|
| RNA, Transfer, Leu | 1 | 2001 | 11 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2001 | 24 | 0.010 |
Why?
|
| Body Fluids | 1 | 2001 | 36 | 0.010 |
Why?
|
| Nitrogen Isotopes | 1 | 2001 | 14 | 0.010 |
Why?
|
| HLA-DR3 Antigen | 1 | 2001 | 1 | 0.010 |
Why?
|
| HLA-DR4 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
| RNA, Transfer, Amino Acyl | 1 | 2001 | 11 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 265 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2002 | 164 | 0.010 |
Why?
|
| Circovirus | 1 | 2000 | 6 | 0.010 |
Why?
|
| Models, Animal | 1 | 2001 | 263 | 0.010 |
Why?
|
| DNA Viruses | 1 | 1999 | 16 | 0.010 |
Why?
|
| Pain | 1 | 2002 | 391 | 0.010 |
Why?
|
| RNA, Transfer | 1 | 2001 | 151 | 0.010 |
Why?
|
| Cholangiography | 1 | 1999 | 41 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1999 | 41 | 0.010 |
Why?
|
| Myocardium | 1 | 2001 | 529 | 0.010 |
Why?
|
| Heart | 1 | 2001 | 539 | 0.010 |
Why?
|
| Survivors | 1 | 1999 | 226 | 0.010 |
Why?
|
| Forecasting | 1 | 1999 | 304 | 0.010 |
Why?
|
| Nuclear Reactors | 1 | 1993 | 8 | 0.010 |
Why?
|
| England | 1 | 1993 | 41 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 1993 | 51 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1992 | 62 | 0.010 |
Why?
|
| Mutation | 1 | 2003 | 3968 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 261 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 375 | 0.010 |
Why?
|
| Morbidity | 1 | 1989 | 148 | 0.010 |
Why?
|
| Mortality | 1 | 1989 | 149 | 0.000 |
Why?
|
| Anastomosis, Surgical | 1 | 1989 | 267 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 763 | 0.000 |
Why?
|
| Esophageal Neoplasms | 1 | 1989 | 321 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1989 | 1076 | 0.000 |
Why?
|